Southern Research Institute today announced that it
is acquiring the bioanalytical laboratory assets and bioanalytical personnel of
BioCryst Pharmaceuticals. Terms of the agreement were not disclosed.
This acquisition will allow Southern Research to expand its
existing bioanalytical
laboratory services, especially in the area of clinical trials support.
“We are happy to have this opportunity to expand our
bioanalytical services and to offer some BioCryst employees an opportunity to
join our team at Southern Research,” said Andrew Penman, Ph.D., vice
president of Drug Development at Southern Research. “This offer will also
keep these scientists and their families in Birmingham, which is important to industry
growth here.”
The bioanalytical lab personnel will continue working in the
BioCryst research facility in Birmingham
until they can be relocated to Southern Research’s Southside Birmingham campus
some time early next year.
